The Wnt signaling pathway is important in hematolymphopoiesis. 1 A critical target of Wnt signaling is b-catenin. b-catenin is normally bound to a multi-protein complex comprising axin, APC, GSK3b, CKIa and PP2A, where b-catenin is phosphorylated by GSK3b, leading to ubiquitylation and proteasome degradation. Activation of the canonical Wnt pathway inhibits GSK3b, resulting in hypophosphorylation and stabilization of b-catenin, which translocates to the nucleus, activates transcription of other target genes, and contributes to tumorigenesis.
Activation of Wnt signaling has been implicated in leukemias. 2, 3 The Wnt inhibitory factor 1 (Wif-1) is an extracellular protein that binds Wnt, negatively regulating the Wnt pathway. 4 Hence, Wif-1 downregulation may contribute to Wnt pathway activation.
In leukemias, promoter hypermethylation of genes involved in cell-cycle control and signaling pathways is frequent. 5, 6 In this study, we tested the hypothesis that epigenetic inactivation of Wif-1 might lead to activation of Wnt signaling in acute leukemia. We further investigated if Wif-1 hypermethylation might be of clinicopathological significance.
Diagnostic bone marrow samples were obtained from 25 patients with acute lymphoblastic leukemia (ALL; T-cell: 2; pre-B: 1; early B-precursor: 3; common: 19), 32 patients with acute promyelocytic leukemia (APL), and 50 patients with other subtypes of acute myeloid leukemia (AML; M1: 12; M2: 20; M4: 6; M5: 9; M6: 3). Five leukemic cell lines, U937, HL60, Raji, Jurkat and NB4 were also tested. Methylation-specific polymerase chain reaction (MSP) for aberrant promoter methylation was performed as described. 5 The primers for the methylated (M-MSP) and unmethylated (U-MSP) promoters of Wif-1 are shown in Table 1 . 7 DNA from eight normal bone marrow donors was used as negative control, while methylated control DNA (CpGenome Universal Methylated DNA, Intergen, New York, NY, USA) was used as positive control in all the experiments. Cycling conditions for MSP were as follows: 951C for 4 min; 35 cycles of 951C for 45 s, specific annealing temperature for 30 s, and 721C for 30 s; and a final extension of 10 min at 721C MSP products were electrophoresed in 6% non-denaturing polyacrylamide gel, and visualized under ultraviolet light after staining with ethidium bromide.
None of the normal bone marrow samples showed Wif-1 methylation. The positive and negative controls showed the expected MSP results (Figure 1a ). Direct sequencing of the M-MSP product also confirmed the specificity of the MSP (Figure 1b) . Of the leukemic cell lines examined, Wif-1 was unmethylated in HL60 and Jurkat, but hemizygously methylated in Raji, NB4 and U937 (Figure 2a ). At diagnosis, Wif-1 methylation was detected in five (25%) of 20 ALL patients (Tcell: 1; early B precursor: 1; common: 3). Interestingly, in AML patients, Wif-1 methylation was found only in APL and not in any of the other subtypes of AMLs ( Figure 2b ) (15/32, 47% versus 0/50, P ¼ 0.0001, w 2 -test). To confirm the biological significance of Wif-1 methylation, the APL cell line NB4 was tested. NB4 cells were seeded in 25 cm 2 culture flasks at 10 6 cells/ml, and treated with 3 mM 5-azacytidine (5-AC, Sigma, St Louis, MO, USA) for 5 days. Cells were harvested daily for mRNA. Quantitative polymerase chain reaction (Q-PCR) for Wif-1 was performed with a Wif-1 primer/TaqMan probe set (Assay-on-Demandt Applied Biosystems, Foster City, CA, USA) according to the manufacturer instructions, using GAPDH as the internal reference. Wif-1 expression relative to GAPDH was calculated with the DC T method (User Bulletin #2, PE Biosystems) 8 by subtracting the C T of Wif-1 from GAPDH to obtain DC T . Difference between Wif-1 and GAPDH was given by 2
ÀDCT . As Wif-1 was hemizygously methylated in NB4, there was low baseline gene expression ( Figure 3 ). Demethylation with 5-AC led to progressive upregulation of Wif-1, reaching an approximate 2.5-fold increased expression by day 5. These results confirmed that promoter methylation suppressed Wif-1 gene expression.
The prognostic impact of Wif-1 methylation was analyzed in APL patients. All patients had received all-trans-retinoic acid (ATRA) for induction of complete remission (CR).
9 Consolida-
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tion comprised two courses of daunorubicin (50 mg perm 2 per day Â 2) and cytosine arabinoside (100 mg per m 2 per day Â 5). Relapsed patients received an oral arsenic trioxide-based regimen. 10 In 31 APL patients, Wif-1 methylation was correlated with gender, age, and presentation white cell count. Categorical variables were compared by w 2 -test, and means of continuous variables (age and diagnostic leukocyte count) by Student t-tests. The effect of Wif-1 methylation, age, gender, and presentation white cell count on disease-free survival (DFS) and overall survival (OS) was analyzed by Cox's proportional hazard model. Wif-1 methylation was associated with a younger median age (P ¼ 0.05) and a higher leukocyte count (P ¼ 0.03) ( Table 2) . CR rate was comparable in patients with and without Wif-1 methylation (10/14 (71.4%) versus 13/17 (76.5%), P ¼ 0.99). However, the projected 3-year DFS was significantly inferior in patients with Wif-1 methylation as compared to those without (36.0 versus 74.1%, P ¼ 0.005) (Figure 4) . In multivariate analysis, Wif-1 methylation was the only independent factor negatively impacting on DFS (P ¼ 0.01), whereas gender, age, presentation leukocyte count and additional cytogenetic aberrations had no effect. The projected 5-year OS was comparable in patients with and without Wif-1 methylation (67.4 versus In four ALL samples, S1-3 were methylated, but S4 was not. In four AML samples, none was methylated. In four APL samples, all were methylated. Table 1 Methylation-specific polymerase chain reaction (MSP): primer sequences and reaction conditions Letter to the Editor 76.4%, P ¼ 0.83), because of highly effective salvage treatment by arsenic trioxide.
We showed for the first time that Wif-1 was preferentially methylated in APL and not in other subtypes of AML. This observation is intriguing, as it has been suggested that the leukemogenic potential of the PML/RARA protein in APL may be partly due to the induction of aberrant methylation by DNA methyltransferase recruitment to target gene promoters. The aberrant methylation of the RARb gene in APL might be due to this mechanism. 11 We have also recently shown that the RARA P2 promoter was also aberrantly methylated in APL. 12 Interestingly, recent studies have shown that the Wnt pathway is activated in APL. 13 In this study, we showed a possible mechanism of Wnt activation. In the APL cell line NB4, aberrant promoter methylation of Wif-1 led to gene repression, and demethylation resulted in gene upregulation. Together with the observation of preferential Wif-1 methylation in clinical APL samples, the results demonstrate that epigenetic downregulation of Wif-1 might be an important mechanism leading to activation of the Wnt pathway in APL.
We have shown that CDKN2B (alias p15) methylation was associated with an inferior DFS in APL, 5, 14 which has been independently validated by other researchers. 15 In this study, Wif-1 methylation conferred an inferior DFS on APL patients treated uniformly with ATRA induction therapy. Recent studies have stressed a risk-adapted approach in the therapy of APL, where high-risk patients might receive more intensive treatment. 16 Our results suggest that Wif-1 methylation should be evaluated as a possible prognostic marker in the stratification of treatment for APL patients. Disease-free survival of APL patients. Patients with Wif-1 methylation had a significantly inferior disease survival. 
